期刊文献+

脑靶向多柔比星胶束的制备及体外性质研究 被引量:4

Preparation and in vitro Properties Study of Brain-targeting Doxorubicin Micelles
原文传递
导出
摘要 目的:制备脑靶向多柔比星胶束,并评价其体外理化性质。方法:合成葡萄糖修饰的泊洛沙姆P105衍生物(葡萄糖-泊洛沙姆P105),考察其氢核磁共振(1H-NMR)图谱,计算葡萄糖的偶联率。用透析法以葡萄糖-泊洛沙姆P105制备脑靶向多柔比星胶束,用单因素法考察处方中多柔比星的投药量、二甲基亚砜(DMSO)与水相的比例对胶束包封率和载药量的影响;考察所制胶束的粒径、Zeta电位、形貌、体外释药情况;以星型胶质细胞和小鼠脑微血管内皮(BMVECs)细胞模拟体外血脑屏障(BBB),比较多柔比星水溶液、多柔比星普通胶束、多柔比星胶束透过BBB的转运率。结果:合成的葡萄糖-泊洛沙姆P105的葡萄糖偶联率为88.7%。随着多柔比星投药量和DMSO有机相比例的增加,包封率和载药量均呈先升高后降低的趋势,其中多柔比星为7 mg、DMSO与水相的体积比为0.10∶1时包封率和载药量最好;所制胶束的平均粒径为(26.7±5.4)nm,Zeta电位为(-6.48±0.64)m V,透射电镜照片显示呈球状;体外释药动力学符合Weibull方程;多柔比星胶束的BBB转运率明显高于多柔比星普通胶束。结论:成功制得具有脑靶向功能的多柔比星胶束。 OBJECTIVE: To prepare the brain-targeting doxorubicin micelles and evaluate its physical and chemical properties in vitro. METHODS: The glucose-mediated poloxamer P105 derivatives (glucose-poloxamer P105) was synthesized, its H-NMR was investigated and coupling rate was calculated. Glucose-poloxamer P105 brain-targeting doxorubicin micelles were prepared by dialysis. The effect of doxorubicin dosage and the proportion of DMSO and water phase on micelles encapsulation efficiency and drug loading amount was investigated with single factor. The diameter, the Zeta potential and appearance of micelles were investi- gated. Astrocytes and mice brain microvascular endothelial cells (BMVECs) were used to construct blood-brain barrier (BBB) in vi- tro to compare the transport ratio of doxorubicin solution, doxorubicin ordinary micelles and doxorubicin micelles through BBB. RESULTS: The glucose coupling rate of synthesis glucose-poloxamer P105 was 88.7 %. As the drug feed and DMSO organic phase ratio increased, the entrapment rate and drug-loading amount were increased first and then decreased, especially best in the volume ratio of DMSO and water phase was 0.10 : 1 and 7 mg doxorubicin. The micelles had a mean diameter of (26.7 ± 5.4) nm, and Zeta potential was ( -6.48 ± 0.64) mV. TEM images showed spherical micelles doxorubicin. The drug release kinetics in vitro of mi- celles met the Weibull equation. In the BBB model, drugs transport ratio of glucose-mediated doxorubicin micelles was significantly higher than ordinary ones. CONCLUSIONS: The brain-targeting doxorubicin micelle is obtained successfully.
出处 《中国药房》 CAS 北大核心 2015年第7期972-975,共4页 China Pharmacy
基金 安徽省自然科学基金项目(No.1308085QH139)
关键词 脑靶向 泊洛沙姆P105 葡萄糖 多柔比星 胶束 Brain-targeting Poloxamer P105 Glucose Doxorubicin Micelles
  • 相关文献

参考文献15

二级参考文献114

  • 1陈琤,陈惠金,蒋明华,钱龙华,陈冠仪.脑缺氧缺血对葡萄糖转运蛋白1基因和葡萄糖转运蛋白3基因表达的影响[J].实用儿科临床杂志,2005,20(1):39-41. 被引量:10
  • 2周卫,平其能,王丽杰.羟喜树碱脂质体的粒径对组织分布的影响[J].中国药科大学学报,2005,36(2):125-128. 被引量:15
  • 3李玲,许向阳,周建平.N-正辛基-N′-琥珀酰基壳聚糖胶束的制备及特征研究[J].中国新药杂志,2007,16(7):543-547. 被引量:3
  • 4Yu S, Zhao T, Guo M, et al. Hypoxic preconditioning upregulates glucose transport activity and glucose transporter ( GLUT1 and GLUT3 ) gene expression after acute anoxic exposure in the cultured rat hippocampal neurons and astrocytes. Brain Res, 2008,1211:22-29.
  • 5Joost HG, Bell GI, Best JD, et al. Nomenclature of the GLUT/SLC2A family of sugar/polyol transport facilitators. Am J Physiol Endocrinol Metab, 2002, 282 (4) :E974-976.
  • 6Pessin JE, Bell GI. Mammalian facilitative glucose transporter family: structure and molecular regulation. Annu Rev Physiol, 1992, 54:911-930.
  • 7Kreuter,J.Nanoparticles.Encyclopaedia of Pharmaceutical Technology[J].Marcel Dekker Inc,New York,USA,1994a; 165-190.
  • 8Barratt,G.M.Therapeutic applications of colloidal drug carriers.Pharmaceut.Sci.Tech.Today,2000,3:163-171.
  • 9Couvreur,P.,et al.Controlled drug delivery with nanoparticles:current possibilities and future trends[J].Eur.J.Pharm.Biopharm,1995,41:2-13.
  • 10Pitt,C.G.,Gratzl,M.M.,Kimmel,et al.The degradation of poly (DL-lactide),poly (epsilon-caprolactone),and their copolymers in vivo.Biomaterials[J].Aliphatic polyesters II,1981,2:215-220.

共引文献55

同被引文献86

  • 1赵静,刘艳,解军波,王凤玲,张彦青.中药纳米递药系统的研究进展[J].中华中医药学刊,2022,40(5):134-137. 被引量:7
  • 2Ostrom QT, Gittleman H, Fulop J, et al. CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012 [J]. Neuro Oncol, 2015, 17 Suppl 4: ivl-iv62, doi: 10,1093/neuonc/nov189.
  • 3Ellis HP, Greenslade M, Powell B, et al. Current Challenges in Glioblastoma: Intratumour Heterogeneity, Residual Dis- ease, and Models to Predict Disease Recurrence [J]. Front Oncol, 2015, 5: 251. doi: 10.3389/fonc,2015.00251.
  • 4Lima FR, Kahn SA, Soletti RC, et al. Glioblastoma: therapeutic challenges, what lies ahead [J]. Biochim Biophys Acta, 2012, 1826(2): 338-349. doi: 10,1016/ j.bbcan,2012.05.004.
  • 5Champ CE, Siglin J, Mishra MV, et al. Evaluating changes in radiation treatment volumes from post-operative to same- day planning MRI in High-grade gliomas [J]. Radiat Oncol, 2012, 7: 220. doi: 10,1186/1748-717X-7-220.
  • 6Chen S, Tanaka S, Giannini C, et al. Gliomatosis cerebri: clinical characteristics, management, and outcomes [J]. J Neurooncol, 2013, 112(2): 267-275. doi: 10,1007/sl 1060- 013-1058-x.
  • 7Zhan C, Li B, Hu L, et al. Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine recep- tor ligand [J]. Angew Chem Int Ed Engl, 2011, 50(24): 5482-5485. doi: 10,1002/anie,201100875.
  • 8Lu W, Wan J, She Z, et al. Brain delivery property and ac- celerated blood clearance of cationic albumin conjugated pegylated nanoparticle [J]. J Control Release, 2007, 118(1): 38-53.
  • 9Bolhassani A. Potential efficacy of cell-penetrating peptides for nucleic acid and drug delivery in cancer [J]. Biochim Biophys Acta, 2011, 1816(2): 232-246. doi: 10,1016/ j.bbcan,2011.07.006.
  • 10Chen X, Plasencia C, Hou Y, et al. Synthesis and biological evaluation of dimeric RGD peptide-paclitaxel conjugate as a model for integrin-targeted drug delivery [J]. J Med Chem, 2005, 48(4): 1098-1106.

引证文献4

二级引证文献10

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部